How effective is this treatment in real-world clinical settings? Experts explore this in a poster presented at the 2024 ASCP Annual Meeting.

The need for effective leadership is apparent.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discusses the results of a systematic literature review.

Answer a quick question on psychedelics!

Learn more about the potential of MDMA-assisted psychotherapy.

Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.

Research on MDD treatments seltorexant and Spravato (esketamine) CIII nasal spray shared at 2024 ASCP Annual Meeting.

How does the Voice Lab relate to psychotherapy?

An expert shares 7 principles for clinicians to consider when prescribing multiple medications for a patient.

The panel offers comprehensive insights on adapting narcolepsy treatments for patients who experience adverse effects, achieve partial response, or have a history of substance abuse.

Experts on narcolepsy discuss review the case of a 35-year-old woman with excessive daytime sleepiness and hypnagogic hallucinations and offer their clinical insights on treatment strategies.

The FDA has approved Austedo XR as a once-daily pill treatment option for tardive dyskinesia and Huntington disease chorea control.

Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.

Joseph F. Goldberg, MD, gives a preview of his upcoming panel presentation at the 2024 ASCP Annual Meeting.

Anita H. Clayton, MD, welcomes us all to the 2024 ASCP Annual Meeting!

Onyda XR is the first and only liquid nonstimulant ADHD medication approved in the US and the only approved nonstimulant ADHD medication with nighttime dosing.

What can 2 recent deaths show us about depression and suicidality?

An analysis presented at the ASCP Annual Meeting explored the safety and tolerability of the treatment for alcohol and tobacco use disorders.

Clinicians should carefully weigh the risks and benefits of each prescribed medication for an older adult with neuropsychiatric diseases and periodically review all prescribed medications. Learn more here.

Answer a quick question on psychedelics!

A poster at the 2024 ASCP Annual Meeting shared data from 3 randomized clinical trials on the safety and tolerability of this treatment combination.

From populations to patients.

An expert discusses the potential of smartphones as treatment measurement tools at the 2024 ASCP Annual Meeting.

Improving cognitive function is a primary goal of brain injury rehabilitation and is made possible through the process of neuroplasticity.